Incyte INCY
NASDAQ INCY
$126.75 -1.25 (-0.98%)
As of: Sep 4, 2026 · 3:59 PM EDT

Incyte (INCY) Change in Accured Expenses (2010 - 2026)

Incyte's (INCY) quarterly Change in Accured Expenses came in at -$204.3 million in Q2 2026, up 57.14% YoY from -$130.0 million in Q2 2025, and down 141.16% on a QoQ basis from -$84.7 million in Q1 2026.

Analysis

Incyte (INCY) Change in Accured Expenses (2010 - 2026) Analysis & Trends

Incyte (INCY) has 17 years of Change in Accured Expenses data on file, last reported at -$204.3 million in Q2 2026.

  • Quarterly Change in Accured Expenses rose 57.14% year-over-year to -$204.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$35.4 million (up 76.48% YoY) and the FY2025 annual result came in at -$148.2 million, down 153.13% from the prior year.
  • Change in Accured Expenses eased to -$204.3 million in Q2 2026, from -$84.7 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $138.5 million in Q4 2025 to a low of -$476.7 million in Q2 2025.
  • A 5-year average of $16.2 million and a median of $62.8 million in 2022 frame the typical range for Change in Accured Expenses.
  • Annual changes were most pronounced in 2022 — Change in Accured Expenses surged 2430.46% — and 2025, when it plunged 510.9%.
  • Tracing INCY's Change in Accured Expenses over 5 years: stood at $47.8 million in 2022, then jumped by 143.08% to $116.2 million in 2023, then gained by 11.66% to $129.8 million in 2024, then rose by 6.76% to $138.5 million in 2025, then sank by 247.48% to -$204.3 million in 2026.
  • The last three Change in Accured Expenses figures came in at -$204.3 million (Q2 2026), -$84.7 million (Q1 2026), and $138.5 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 222.50 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 492.70 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 11.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 55.78 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 212.44 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 61.62 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 68.82 Mn
10 Incyte 25.44 Bn 20.91 Bn 1.57 Bn -204.33 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -204.33 Mn
Mar 31, 2026 -84.73 Mn
Dec 31, 2025 138.55 Mn
Sep 30, 2025 115.14 Mn
Jun 30, 2025 -476.73 Mn
Mar 31, 2025 74.84 Mn
Dec 31, 2024 129.77 Mn
Sep 30, 2024 121.74 Mn
Jun 30, 2024 -78.04 Mn
Mar 31, 2024 105.47 Mn
Dec 31, 2023 116.22 Mn
Sep 30, 2023 21.89 Mn
Jun 30, 2023 20.60 Mn
Mar 31, 2023 71.90 Mn
Dec 31, 2022 47.81 Mn
Sep 30, 2022 120.73 Mn
Jun 30, 2022 -2.14 Mn
Mar 31, 2022 53.79 Mn
Dec 31, 2021 46.40 Mn
Sep 30, 2021 91.42 Mn